Author

B. Parejo-Alonso

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. Heeschen· 3 shared P. Sancho· 3 shared S. Courtois· 3 shared A. Royo-Garcia· 2 shared B. Sainz· 2 shared L. Penin-Peyta· 2 shared P. Espiau-Romera· 2 shared P. Jagust· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Heeschen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ALK signaling drives tumorigenicity and chemoresistance of pancreatic ductal adenocarcinoma cells

B. Parejo-Alonso, A. Royo-Garcia, P. Espiau-Romera, S. Courtois, A. Curiel-Garcia, S. Zagorac, I. Villaoslada, K. P. Olive, C. Heeschen, P. Sancho

This study shows that ALK signaling promotes tumorigenicity and chemoresistance in pancreatic cancer stem cells, and that ALK inhibitors can reduce CSC content and enhance chemotherapy effectiveness.

bioRxiv · Aug 29, 2022 · PreprintCancer Biology

PPAR-delta acts as a metabolic master checkpoint for metastasis in pancreatic cancer

B. Parejo-Alonso, D. Barneda, S. M. Trabulo, S. Courtois, S. Compte-Sancerni, L. Ruiz-Canas, Q. Zheng, J. Tang, M. Chen, Z. Guo, U. Schmitz, P. Irun, L. Penin-Peyta, S. M. Crusz, A. Cano-Galiano, , P. Sancho

This study shows PPAR-delta drives metabolic reprogramming in pancreatic cancer, promoting metastasis, and its inhibition reduces invasiveness.

bioRxiv · Nov 15, 2021 · PreprintCancer Biology

Inhibition of mitochondrial dynamics preferentially targets pancreatic cancer cells with enhanced tumorigenic and invasive potential

S. Courtois, B. de Luxan-Delgado, L. Penin-Peyta, A. Royo-Garcia, B. Parejo-Alonso, P. Jagust, S. Alcala, J. A. Rubiolo, L. Sanchez, B. Sainz, C. Heeschen, P. Sancho

This study shows that inhibiting mitochondrial fission with mDivi-1 selectively kills pancreatic cancer stem cells by causing mitochondrial dysfunction and energy crisis.

bioRxiv · Jan 17, 2021Cancer Biology